(Total Views: 537)
Posted On: 05/30/2019 12:27:43 PM
Post# of 30066
*Cutanogen is positioning ESS to enter pivotal-stage clinical development for the treatment
of deep thermal pediatric severe burns covering over 30% TBSA.
Note 11 – Significant Transactions and Important Additional Information
On November 27, 2018, the Company confidentially filed a Regulation A+ offering (the “Reg A+”) with the U.S. Securities and Exchange Commission (the “SEC”) to raise a maximum of $20,000,000 in common stock at a fixed price of between $0.01 and $1 per share. The Company received comments on the Reg A+ from the SEC on December 21st, 2018. The Company expects to update its filing to include the recent evaluation of expansion of its business operations to include the federally legal hemp space, update for these first quarter financials, and also respond to theSEC comments in the second quarter of 2019. The final per share price of the Reg A+ offering will be determined by Amarantus management immediately prior to the offering becoming qualified and open for investment.
Aloha
of deep thermal pediatric severe burns covering over 30% TBSA.
Note 11 – Significant Transactions and Important Additional Information
On November 27, 2018, the Company confidentially filed a Regulation A+ offering (the “Reg A+”) with the U.S. Securities and Exchange Commission (the “SEC”) to raise a maximum of $20,000,000 in common stock at a fixed price of between $0.01 and $1 per share. The Company received comments on the Reg A+ from the SEC on December 21st, 2018. The Company expects to update its filing to include the recent evaluation of expansion of its business operations to include the federally legal hemp space, update for these first quarter financials, and also respond to theSEC comments in the second quarter of 2019. The final per share price of the Reg A+ offering will be determined by Amarantus management immediately prior to the offering becoming qualified and open for investment.
Aloha
(2)
(0)
